Henlius will receive $143.39M up front & milestones along with royalties. Fosun to get the right to commercialize Henlius’ HANSIZHUANG (anti-PD-1 mAb) in the US by using its capabilities & provides the patients’ benefits globally while Henlius will lead the development, manufacturing & supply
The companies focus to develop HANSIZHUANG, integrating superior resources & promoting the US launch. The companies collaborated on product commercialization & other areas, understanding corporate vision & values, development strategy, product operations & management communication, focusing on patients’ & clinical needs
The international medical journal published HANSIZHUANG’s clinical data. The product was approved in China for MSI-H solid tumors & sq.NSCLC; ODD for SCLC in the US & EC
Ref: Globenewswire | Image: Nanobiotix
Related News:- Henlius’ Hansizhuang (serplulimab) Receives NMPA’s Approval for the Treatment of Squamous Non-Small Cell Lung Cancer
